These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28257991)

  • 1. Low-dose controlled release of mTOR inhibitors maintains T cell plasticity and promotes central memory T cells.
    Gammon JM; Gosselin EA; Tostanoski LH; Chiu YC; Zeng X; Zeng Q; Jewell CM
    J Control Release; 2017 Oct; 263():151-161. PubMed ID: 28257991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTOR inhibition improves antitumor effects of vaccination with antigen-encoding RNA.
    Diken M; Kreiter S; Vascotto F; Selmi A; Attig S; Diekmann J; Huber C; Türeci Ö; Sahin U
    Cancer Immunol Res; 2013 Dec; 1(6):386-92. PubMed ID: 24778131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination.
    Huye LE; Nakazawa Y; Patel MP; Yvon E; Sun J; Savoldo B; Wilson MH; Dotti G; Rooney CM
    Mol Ther; 2011 Dec; 19(12):2239-48. PubMed ID: 21878902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled delivery of a metabolic modulator promotes regulatory T cells and restrains autoimmunity.
    Gammon JM; Tostanoski LH; Adapa AR; Chiu YC; Jewell CM
    J Control Release; 2015 Jul; 210():169-78. PubMed ID: 26002150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunity.
    Li Q; Rao R; Vazzana J; Goedegebuure P; Odunsi K; Gillanders W; Shrikant PA
    J Immunol; 2012 Apr; 188(7):3080-7. PubMed ID: 22379028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells.
    Wang C; Yi T; Qin L; Maldonado RA; von Andrian UH; Kulkarni S; Tellides G; Pober JS
    J Clin Invest; 2013 Apr; 123(4):1677-93. PubMed ID: 23478407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dominant role of antigen dose in CD4+Foxp3+ regulatory T cell induction and expansion.
    Turner MS; Kane LP; Morel PA
    J Immunol; 2009 Oct; 183(8):4895-903. PubMed ID: 19801514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of mechanistic target of rapamycin promotes dendritic cell activation and enhances therapeutic autologous vaccination in mice.
    Amiel E; Everts B; Freitas TC; King IL; Curtis JD; Pearce EL; Pearce EJ
    J Immunol; 2012 Sep; 189(5):2151-8. PubMed ID: 22826320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines.
    Wang Y; Wang XY; Subjeck JR; Shrikant PA; Kim HL
    Br J Cancer; 2011 Feb; 104(4):643-52. PubMed ID: 21285988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4+Foxp3+ regulatory T cells converted by rapamycin from peripheral CD4+CD25(-) naive T cells display more potent regulatory ability in vitro.
    Chen JF; Gao J; Zhang D; Wang ZH; Zhu JY
    Chin Med J (Engl); 2010 Apr; 123(7):942-8. PubMed ID: 20497692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin-sensitive signals control TCR/CD28-driven Ifng, Il4 and Foxp3 transcription and promoter region methylation.
    Tomasoni R; Basso V; Pilipow K; Sitia G; Saccani S; Agresti A; Mietton F; Natoli G; Colombetti S; Mondino A
    Eur J Immunol; 2011 Jul; 41(7):2086-96. PubMed ID: 21480212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity.
    Berezhnoy A; Castro I; Levay A; Malek TR; Gilboa E
    J Clin Invest; 2014 Jan; 124(1):188-97. PubMed ID: 24292708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance.
    Turnquist HR; Raimondi G; Zahorchak AF; Fischer RT; Wang Z; Thomson AW
    J Immunol; 2007 Jun; 178(11):7018-31. PubMed ID: 17513751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled Release of Second Generation mTOR Inhibitors to Restrain Inflammation in Primary Immune Cells.
    Gosselin EA; Tostanoski LH; Jewell CM
    AAPS J; 2017 Jul; 19(4):1175-1185. PubMed ID: 28484962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation.
    Reichardt W; Dürr C; von Elverfeldt D; Jüttner E; Gerlach UV; Yamada M; Smith B; Negrin RS; Zeiser R
    J Immunol; 2008 Oct; 181(7):4770-9. PubMed ID: 18802080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective expansion of merocytic dendritic cells and CD8DCs confers anti-tumour effect of Fms-like tyrosine kinase 3-ligand treatment in vivo.
    Hennies CM; Reboulet RA; Garcia Z; Nierkens S; Wolkers MC; Janssen EM
    Clin Exp Immunol; 2011 Mar; 163(3):381-91. PubMed ID: 21235535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine dendritic cell rapamycin-resistant and rictor-independent mTOR controls IL-10, B7-H1, and regulatory T-cell induction.
    Rosborough BR; Raïch-Regué D; Matta BM; Lee K; Gan B; DePinho RA; Hackstein H; Boothby M; Turnquist HR; Thomson AW
    Blood; 2013 May; 121(18):3619-30. PubMed ID: 23444404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg.
    Biswas M; Sarkar D; Kumar SR; Nayak S; Rogers GL; Markusic DM; Liao G; Terhorst C; Herzog RW
    Blood; 2015 May; 125(19):2937-47. PubMed ID: 25833958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.
    Duewell P; Kisser U; Heckelsmiller K; Hoves S; Stoitzner P; Koernig S; Morelli AB; Clausen BE; Dauer M; Eigler A; Anz D; Bourquin C; Maraskovsky E; Endres S; Schnurr M
    J Immunol; 2011 Jul; 187(1):55-63. PubMed ID: 21613613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maturation of dendritic cells by pullulan promotes anti-cancer effect.
    Zhang W; Yu X; Kwak M; Xu L; Zhang L; Yu Q; Jin JO
    Oncotarget; 2016 Jul; 7(28):44644-44659. PubMed ID: 27341129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.